Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease
Main finding · CV eventsResult — go to the resultAdjusted hazard ratio 9.05 CI 3.24–25.3Authors' conclusion
NT-proBNP provides prognostic information beyond a conventional risk marker model in patients with ACHD and can reliably exclude the risk of death and heart failure. Elevated levels of NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15 identify patients at highest risk of cardiovascular events.
Study context
- Population
- Clinically stable outpatients with adult congenital heart disease (ACHD), April 2011–April 2013
- Participants
- 595 outpatients
- Exposure
- NT-proBNP, high-sensitive troponin-T and GDF-15 levels and CV events
- Outcome
- CV events:
- Death
- HF
- Hospitalization
- Arrhythmia
- Thromboembolic events
- Reintervention
- Follow-up
- Median 42 (IQR 37-46) months
Main finding
CV events
Adjusted hazard ratio
9.05
CI 3.24–25.3
P < 0.001
NT-proBNP upper quartile
adjusted HR 9.05 (CI 3.24–25.3); P < 0.001
As reported in the abstract
- Elevated NT-proBNP (>14 pmol/L), hs-troponin-T (>14 ng/L) and GDF-15 (>1109 ng/L) identified those at highest risk of CV events
- log-rank P<0.0001
Observational data: associations, not effects.
Further findings
Death or HF
| Comparison | Adjusted HR (CI) | P value | |
|---|---|---|---|
| NT-proBNP upper quartilen=50 events | 16.0 (2.04–126) | P < 0.001 | |
| 0.050.21520Adjusted hazard ratio (log scale) |
- Death or HF — Cumulative proportion with death and HF in lowest 2 NT-proBNP quartiles
- 1%
Original publication
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease. Circulation. Published 3 November 2016. doi:10.
Summarised from the published abstract; every number is checked against it